Factors Associated With Readmission in the United States Following Hospitalization With Coronavirus Disease 2019.
Autor: | Verna EC; Columbia University Irving Medical Center, NewYork, New York, USA., Landis C; University of Washington, Seattle, Washington, USA., Brown RS; Weill Cornell, New York, New York, USA., Mospan AR; Target RWE Health Evidence Solutions, Durham, North Carolina, USA., Crawford JM; Target RWE Health Evidence Solutions, Durham, North Carolina, USA., Hildebrand JS; Target RWE Health Evidence Solutions, Durham, North Carolina, USA., Morris HL; Target RWE Health Evidence Solutions, Durham, North Carolina, USA., Munoz B; Target RWE Health Evidence Solutions, Durham, North Carolina, USA., Fried MW; Target RWE Health Evidence Solutions, Durham, North Carolina, USA., Reddy KR; University of Pennsylvania, Philadelphia, Pennsylvania, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 May 30; Vol. 74 (10), pp. 1713-1721. |
DOI: | 10.1093/cid/ciab464 |
Abstrakt: | Background: Patients hospitalized for coronavirus disease 2019 (COVID-19) may experience complications following hospitalization and require readmission. In this analysis, we estimated the rate and risk factors associated with COVID-19-related readmission and inpatient mortality. Methods: In this retrospective cohort study, we used deidentified chargemaster data from 297 hospitals across 40 US states on patients hospitalized with COVID-19 from 15 February 2020 through 9 June 2020. Demographics, comorbidities, acute conditions, and clinical characteristics of first hospitalization are summarized. Multivariable logistic regression was used to measure risk factor associations with 30-day readmission and in-hospital mortality. Results: Among 29 659 patients, 1070 (3.6%) were readmitted. Readmitted patients were more likely to have diabetes, hypertension, cardiovascular disease (CVD), or chronic kidney disease (CKD) vs those not readmitted (P < .0001) and to present on first admission with acute kidney injury (15.6% vs 9.2%), congestive heart failure (6.4% vs 2.4%), or cardiomyopathy (2.1% vs 0.8%) (P < .0001). Higher odds of readmission were observed in patients aged >60 vs 18-40 years (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.48-2.50) and those admitted in the Northeast vs West (OR, 1.43; 95% CI, 1.14-1.79) or South (OR, 1.28; 95% CI, 1.11-1.49). Comorbidities including diabetes (OR, 1.34; 95% CI, 1.12-1.60), CVD (OR, 1.46; 95% CI, 1.23-1.72), CKD stage 1-5 (OR, 1.51; 95% CI, 1.25-1.81), and CKD stage 5 (OR, 2.27; 95% CI, 1.81-2.86) were associated with higher odds of readmission; 12.3% of readmitted patients died during second hospitalization. Conclusions: Among this large US population of patients hospitalized with COVID-19, readmission was associated with certain comorbidities and acute conditions during first hospitalization. These findings may inform strategies to mitigate risks of readmission due to COVID-19 complications. (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.) |
Databáze: | MEDLINE |
Externí odkaz: |